Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
Clinical role
DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
Images and patients
Radiotherapy Planning Imaging · Brain tumors, including metastases, meningiomas, and acoustic neuromas
Key limitation
Keep in mind: The clinician must confirm and modify contours in the treatment-planning system; adult population and listed tumor scope are not extended.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
Which images or clinical context are in scope?Modality: Radiotherapy Planning Imaging Anatomy or clinical context: Brain tumors, including metastases, meningiomas, and acoustic neuromas Input: CT or MR treatment-planning images, target structures, organs-at-risk information, and other labeled planning inputs.
Who uses it?Intended users: Radiation oncologists, medical physicists, dosimetrists, and other qualified professionals within the exact labeled treatment-planning workflow.
What does the software produce?Output: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.
What is its most important limitation?Key limitation: The clinician must confirm and modify contours in the treatment-planning system; adult population and listed tumor scope are not extended.
Clinical takeaway. Clinical role: DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a multicenter, multinational, retrospective standalone study of 136 cases with 360 lesions from 16 institutions (15 in the US and 1 non-US), with ground truth by consensus of three US board-certified radiologists. With bi-parametric MR images (T1W+C and T2W), lesion-wise sensitivity was 88.6% (95% CI 85.3% to 91.9%), false positive rate 0.537 tumors/case, and lesion-wise Dice coefficient 0.809 (0.793 to 0.824); with single-parametric images, 88.3%, 0.787 tumors/case and 0.804. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
DeepBT Detector-Plus provides initial gross-tumor-volume contours on T1-weighted contrast-enhanced and optional T2-weighted MR images for radiation-treatment planning in adults with the labeled brain tumors.
The exact FDA document reports a multicenter, multinational, retrospective standalone study of 136 cases with 360 lesions from 16 institutions (15 in the US and 1 non-US), with ground truth by consensus of three US board-certified radiologists. With bi-parametric MR images (T1W+C and T2W), lesion-wise sensitivity was 88.6% (95% CI 85.3% to 91.9%), false positive rate 0.537 tumors/case, and lesion-wise Dice coefficient 0.809 (0.793 to 0.824); with single-parametric images, 88.3%, 0.787 tumors/case and 0.804. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "AItewan conducted a multicenter, multinational, retrospective study to evaluate the standalone analytical performance of the artificial intelligence software" … "The test dataset consisted of 136 cases with 360 lesions, retrospectively collected from 16 different institutions (15 in the US and 1 non-US).". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a multicenter, multinational, retrospective standalone study of 136 cases with 360 lesions from 16 institutions (15 in the US and 1 non-US), with ground truth by consensus of three US board-certified radiologists. With bi-parametric MR images (T1W+C and T2W), lesion-wise sensitivity was 88.6% (95% CI 85.3% to 91.9%), false positive rate 0.537 tumors/case, and lesion-wise Dice coefficient 0.809 (0.793 to 0.824); with single-parametric images, 88.3%, 0.787 tumors/case and 0.804. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "AItewan conducted a multicenter, multinational, retrospective study to evaluate the standalone analytical performance of the artificial intelligence software" … "The test dataset consisted of 136 cases with 360 lesions, retrospectively collected from 16 different institutions (15 in the US and 1 non-US).". Read from the exact FDA decision document on 2026-11-14.
Standalone lesion-wise sensitivity for brain tumors on 136 cases with 360 lesions: 88.6% (95% CI 85.3% to 91.9%) with bi-parametric MR images (T1W+C and T2W); 88.3% (95% CI 85.0% to 91.6%) with single-parametric MR images (T1W+C).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "The test dataset consisted of 136 cases with 360 lesions, retrospectively collected from 16 different institutions (15 in the US and 1 non-US)." … "Table 2. Performance data of bi-parametric MR images (T1W+C and T2W) Performance Metrics Overall Value 95% Confidence Interval Lesion-wise Sensitivity 88.6% 85.3% to 91.9%". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No exact-product, version-specific specificity endpoint was established for this submission in the evidence set.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K252190 FDA evidence package for DeepBT Detector-Plus
DesignFDA submission-level decision material with device, software, performance, safety, and/or usability verification as applicable; not independent clinical validation.
PopulationPopulation and workflow are limited to the exact FDA labeling summarized for this submission.
Scopeexact submission
Tested versionExact FDA submission release; version not separately stated in the public decision material
IndependenceSponsor or vendor study
K252190
Evidence submitted for the exact FDA decision is not independent clinical validation. Local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252190 by native exact submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS radiation-oncology material. Evaluate net planning or delivery value within the radiotherapy service line.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: CT or MR treatment-planning images, target structures, organs-at-risk information, and other labeled planning inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Produces initial contours for review and editing in a compatible DICOM treatment-planning system or workstation; local import, export, and approval workflow require acceptance.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. Deployment details for the exact cleared configuration are not established in the public FDA decision material.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 ·
Returned objects
Source context, not route validation: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Contours, dose predictions, synthetic CT, registration, or other treatment-planning information described in the exact FDA labeling.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Produces initial contours for review and editing in a compatible DICOM treatment-planning system or workstation; local import, export, and approval workflow require acceptance.
Use by the qualified healthcare professionals identified for the exact labeled workflow; site-specific competency and training requirements remain to be established locally.
Produces initial contours for review and editing in a compatible DICOM treatment-planning system or workstation; local import, export, and approval workflow require acceptance.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The clinician must confirm and modify contours in the treatment-planning system; adult population and listed tumor scope are not extended.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the evidence set; productivity or value claims require local evidence.
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes; exact monitoring thresholds and vendor commitments are unknown.
exact submission · checked 2026-09-04
Establish ownership for data quality, overrides, drift, incidents, recalls, and change control.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, fda decision summary, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found in the evidence set. Obtain a written quote covering license or hardware basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, downtime, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Deployment: Not verified - checked 2026-09-04 - Exact FDA submission
Deployment details for the exact cleared configuration are not established in the public FDA decision material.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Security controls, hosting boundaries, audit behavior, identity management, and incident commitments for the exact configuration are not established in the public FDA decision material.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-04 - Exact FDA submission
Post-deployment monitoring, drift thresholds, alerting, and revalidation commitments for the exact configuration require vendor and site confirmation.
Authorized purpose: MVision AI Segmentation automatically generates initial contours from CT images for radiotherapy planning; the contours are transferred for professional visualization, review, modification, and approval, and the labeled software is not intended for lesion or tumor detection or real-time adaptive planning.
Modality
Radiotherapy Planning Imaging
Anatomy
Head and neck, brain, breast, lung and abdomen, male pelvis, and female pelvis structures
Authorized purpose: syngo.via RT Image Suite VC10 provides three-dimensional and four-dimensional multimodality visualization, registration, fusion, contouring, and planning support for radiation-treatment preparation.
Modality
Radiotherapy Planning Imaging
Anatomy
Brain, pelvis, thorax, abdomen, targets, organs at risk, and moving tumors or organs
Authorized purpose: The EMLA family delivers external-beam radiation therapy for adult and pediatric patients with benign, malignant, or metastatic disease. Authorized techniques vary by model: Synergy and Harmony include conventional and fractionated delivery; Infinity and Harmony Pro add SBRT/SABR; Versa HD and Evo also support SRS and specified functional disorders.
Authorized purpose: TAIMedImg DeepMets assists trained professionals by providing initial gross-tumor-volume contours on axial contrast-enhanced T1 brain MR images for radiation-treatment planning in adults with known brain metastases; the contours require thorough review and are not a replacement for manual contouring.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.